Just when the world thought the era of unpredictable COVID variants was behind us, a highly mutated new strain has emerged with a name that perfectly describes its eerie behavior: “Cicada.” Officially designated as BA.3.2, this variant is currently raising serious questions among virologists and public health officials as it begins to surface in dozens of countries, including at least 25 U.S. states.

The nickname “Cicada” was coined by evolutionary biologists because of the strain’s unique “hibernation” pattern. Much like the insect that spends years beneath the earth before suddenly swarming, BA.3.2 was actually first identified in South Africa back in late 2024. For nearly two years, it remained in the shadows, circulating at such low levels that it barely registered on global surveillance maps. However, in early 2026, it “emerged” with a startling surge in detections across Europe and North America.

What has scientists like Dr. Andrew Pekosz of Johns Hopkins truly concerned is the variant’s genetic makeup. BA.3.2 carries an unprecedented 70 to 75 mutations in its spike protein—the part of the virus that attaches to human cells. To put that in perspective, this is the most significant genetic shift seen since the original Omicron wave. These mutations make the Cicada variant look vastly different to our immune systems compared to the JN.1 and LP.8.1 strains that the current 2025–2026 vaccines were designed to target.

Because of this “highly divergent” nature, early laboratory data suggests that BA.3.2 is a master of immune escape. Researchers at the CDC and international labs have found that the antibodies generated by previous infections or the most recent booster shots are less effective at neutralizing this specific strain. In parts of Denmark and Germany, the variant has already climbed to represent 30% of all sequenced cases, signaling that it may have a competitive edge in spreading through populations that already have high levels of immunity.

However, the news isn’t all grim. While the Cicada variant is proving to be a “ghost” that can slip past some of our defenses, there is currently no evidence that it causes more severe disease or higher mortality rates. Symptoms reported so far mirror other recent Omicron descendants: a painful “razorblade” sore throat, fatigue, congestion, and cough. Some patients have noted a higher frequency of night sweats, but the classic loss of taste and smell remains rare.

Crucially, experts emphasize that while the vaccine’s ability to prevent infection from BA.3.2 might be reduced, its ability to prevent hospitalization and death remains robust. Our T-cells—the “heavy lifters” of the immune system—still recognize enough of the virus to keep most people out of the ICU.

As of late March 2026, the Cicada variant still accounts for a small fraction of total U.S. cases, but its presence in wastewater surveillance from Hawaii to New York suggests it is spreading much faster than clinical tests show. Whether it will fuel a summer surge or remain a background threat depends on how quickly it evolves. For now, the message from health officials is one of “measured vigilance.” The Cicada has emerged, and while it might not be a “killer” strain, it is a powerful reminder that the virus is still finding clever ways to stay in the game.